Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12258418
Claudin18.2 binding moieties and uses thereof
granted -
US 12258412
Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12258372
Recombinant vaccine against Marek's disease and Newcastle disease
granted -
US 12258370
Betulastatin compounds
granted -
US 12258341
IRAK degraders and uses thereof
granted -
US 12258317
Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof
granted -
US 12258316
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 12257325
Chelating platform for delivery of radionuclides
granted -
US 12257288
Methods of inducing immune tolerance to clotting factors
granted -
US 12257311
Multimeric T-cell modulatory polypeptides and methods of use thereof
granted -
US 12257306
Antiviral prodrugs and nanoformulations thereof
granted -
US 12257263
Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
granted -
US 12257262
Method of reconstituting liposomal annamycin
granted -
US 12257242
Inhibition of crystal growth of roflumilast
granted -
US 12257247
Targeted degradation of VAV1
granted -
US 12257132
Hydrogen-delivering system for a bodily orifice
granted -
US 12257224
Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
granted -
US 12258366
Bicyclic heteroaryl compounds and uses thereof
granted -
US 12257277
Adeno-associated virus formulations
granted -
US 12257235
Methods and materials for using ruminococcus gnavus or clostridium sporogenes to treat gastrointestinal disorders
granted -
US 12258354
AhR modulators
granted -
US 12258425
Peptide compositions and methods of use
granted -
US 12257352
Compositions and methods for delivery of biomacromolecule agents
granted -
US 12257278
Methods of treating cancer with TNF expressing myxoma virus
granted -
US 12257261
Preparation of preliposomal Annamycin lyophilizate
granted -
US 12257326
TCO conjugates and methods for delivery of therapeutic agents
granted -
US 12256720
Humanized dipeptidyl-peptidase IV (DPP4) animals
granted -
US 12257266
Stem cell-derived exosomes for the treatment of corneal scarring
granted -
US 12258333
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
granted -
US 12257302
Universal vaccine platform
granted -
US 12258367
Glucoside derivative that acts as SGLT1 inhibitor and application thereof
granted -
US 12259378
Dynamic clamps and methods of use thereof
granted -
AR 131518
COMPUESTO DE 4-AMINOPIPERIDINA, NANOPARTÍCULAS LIPÍDICAS DEL MISMO Y COMPOSICIÓN FARMACÉUTICA QUE CONTIENE EL MISMO
granted -
WO 2025064824
MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER
granted -
WO 2025062334
DÉRIVÉS DE 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZÈNESULFONAMIDE ET COMPOSÉS SIMILAIRES UTILISÉS COMME INHIBITEURS DE CDK POUR LE TRAITEMENT DU CANCER
granted -
US 12266425
T cell receptor sequences diagnostic for COVID-19 and related compositions
granted -
US 12264366
Genome-based methods for reducing cardiovascular risk
granted -
US 12264344
Protein/oligonucleotide core-shell nanoparticle therapeutics
granted -
US 12264343
TCRa homing endonuclease variants
granted -
US 12264322
Minimal volume reprogramming of mononuclear cells
granted -
US 12264187
Compositions and methods for targeted therapeutic delivery to bone
granted -
US 12264169
Heteroaryl inhibitors of PDE4
granted -
US 12264167
Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
granted -
US 12263250
Nanofiber segments and methods of use thereof
granted -
US 12264158
Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
granted -
US 12263325
Device, system and methods for the oral delivery of therapeutic compounds
granted -
US 12263225
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.